Rasmusson Elisabeth, Nilsson Per, Kjellén Elisabeth, Gunnlaugsson Adalsteinn
Department of Hematology, Oncology and Radiation Physics, Skane University Hospital, Lund, Sweden.
Lund University, Faculty of Medicine, Department of Clinical Sciences, Lund, Oncology and Pathology, Lund, Sweden.
Adv Radiat Oncol. 2020 Sep 28;6(1):100571. doi: 10.1016/j.adro.2020.09.011. eCollection 2021 Jan-Feb.
The aim of the present study was to analyze the long-term incidence of hip complications after external beam radiation therapy compared with age-matched controls from the general population. We also investigated whether there were any dose-response associations.
A total of 349 patients with prostate cancer treated to curative dose with external beam radiation therapy between 1997 and 2002 were included in the study. Physical and fractionation-corrected dose-volume descriptors were derived for the femoral heads, pubic bone, and sacrum. Information on skeletal events was collected for the patients and 1661 matched controls through the Prostate Cancer database Sweden. Uni- and multivariable Cox proportional hazard regressions were used to analyze the time to event.
Data from 346 patients were available for analysis. The median mean physical dose and corresponding equivalent 2-Gy/fraction dose (EQD2) to the femoral heads were 35.5 Gy and 28.7 Gy, respectively. The median follow-up time was 16.0 years. During the follow up, 12 hip fractures occurred. Hip osteoarthritis was diagnosed in 36 cases, with 29 cases leading to replacement surgery. No increased risk of hip fractures was found. Hip osteoarthritis was the only event for which a statistically significant difference was found between the irradiated cohort and the controls (cause-specific hazard ratio: 1.56; 95% confidence interval, 1.07-2.26; = .02). The cumulative incidence of osteoarthritis at 10 years was 8.1% and 4.9% in the irradiated cohort and the controls, respectively. A significant relationship between osteoarthritis and the volume of the femoral head receiving ≥40 Gy (ie, EQD2) was found.
In this study of 346 patients treated with conventional radiation therapy, we found no increased risk of hip fracture but an increased risk of clinically relevant osteoarthritis at long-term follow up. Our results indicate a dose-response relationship between osteoarthritis and the volume of the femoral head receiving an EQD2 dose of ≥40 Gy.
本研究旨在分析与来自普通人群的年龄匹配对照组相比,外照射放疗后髋部并发症的长期发生率。我们还调查了是否存在任何剂量反应关联。
本研究纳入了1997年至2002年间接受外照射放疗至根治剂量的349例前列腺癌患者。得出了股骨头、耻骨和骶骨的物理及分次校正剂量体积描述符。通过瑞典前列腺癌数据库收集了患者和1661名匹配对照的骨骼事件信息。使用单变量和多变量Cox比例风险回归分析事件发生时间。
346例患者的数据可供分析。股骨头的中位平均物理剂量及相应的等效2 Gy/分次剂量(EQD2)分别为35.5 Gy和28.7 Gy。中位随访时间为16.0年。随访期间,发生了12例髋部骨折。诊断出36例髋骨关节炎,其中29例导致置换手术。未发现髋部骨折风险增加。髋骨关节炎是照射队列与对照组之间唯一发现有统计学显著差异的事件(病因特异性风险比:1.56;95%置信区间,1.07 - 2.26;P = .02)。照射队列和对照组中骨关节炎在10年时的累积发生率分别为8.1%和4.9%。发现骨关节炎与接受≥40 Gy(即EQD2)的股骨头体积之间存在显著关系。
在这项对346例接受传统放疗患者的研究中,我们发现在长期随访中髋部骨折风险未增加,但临床相关骨关节炎风险增加。我们的结果表明骨关节炎与接受EQD2剂量≥40 Gy的股骨头体积之间存在剂量反应关系。